NCT02102698

Ecopipam Treatment of Tourette's Syndrome in Subjects 7-17 Years

• Status: Completed
• Phase: Phase 2
• Study type: Interventional
• Enrollment: 40 (actual)
• Sponsor: Emalex Biosciences Inc. · Industry
• Sex: All
• Age: 7 Years – 17 Years
• Healthy volunteers: Not accepted

Summary

Tourette's Syndrome is a neurological disease characterized by motor and vocal tics. It has been hypothesized that abnormal interactions of dopamine with its receptors may cause the tics. The purpose of this study is to test the hypothesis that a drug (ecopipam) that selectively blocks dopamine D1/D5 receptors can reduce the frequency and severity of the tics.

Detailed description

This is a double blind, randomized, placebo-controlled crossover study to determine whether ecopipam can reduce the symptoms of Tourette's in children age 7-17 years.

Conditions

• Tourette's Syndrome

Interventions

Type	Name	Description
DRUG	Ecopipam	Ecopipam is a selective antagonist of the dopamine D1 receptor family.

Timeline

• Start date: 2014-03-01
• Primary completion: 2019-12-01
• Completion: 2019-12-01
• First posted: 2014-04-03
• Last updated: 2024-04-19

Locations

11 sites across 1 country: United States